DINAMIQS Expands with New Lab in Zurich

On November 12, 2024, Siegfried AG announced the inauguration of new state-of-the-art laboratories by its subsidiary DINAMIQS in Zurich's Bio-Technopark, Switzerland. Siegfried, a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical sector, is strengthening its capabilities in the growing field of biologics, particularly cell and gene therapy.

The new lab, equipped with high-end pilot-scale equipment, will support clinical viral vector development along with analytical and manufacturing services. It is part of a larger 2,500m2 cGMP manufacturing facility set to launch by the end of 2025, aiming for a production capacity of up to 1,000L for R&D, clinical trials, and commercial use.

Executives from Siegfried and DINAMIQS emphasized the milestone's alignment with strategic goals and the comprehensive services now available to clients from genome optimization to GMP scale-up.